|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Carteolol#Pharmacology]] |
| {{Carteolol}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Clinical Pharmacology==
| |
| | |
| Carteolol HCl is a nonselective beta-adrenergic blocking agent with associated intrinsic sympathomimetic activity and without significant membrane-stabilizing activity.
| |
| | |
| Ocupress (carteolol HCl) reduces normal and elevated [[intraocular pressure]] ([[IOP]]) whether or not accompanied by [[glaucoma]]. The exact mechanism of the ocular hypotensive effect of beta-blockers has not been definitely demonstrated.
| |
| | |
| In general, beta-adrenergic blockers reduce cardiac output in patients in good and poor cardiovascular health. In patients with severe impairment of myocardial function, beta-blockers may inhibit the sympathetic stimulation necessary to maintain adequate cardiac function. Beta-adrenergic blockers may also increase airway resistance in the bronchi and bronchioles due to unopposed parasympathetic activity.
| |
| | |
| Given topically twice daily in controlled domestic clinical trials ranging from 1.5 to 3 months, Ocupress produced a median percent reduction of [[IOP]] 22% to 25%. No significant effects were noted on corneal sensitivity, tear secretion, or pupil size.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ZEBETA (BISOPROLOL FUMARATE) TABLET [DURAMED PHARMACEUTICALS, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a11548a0-9c0f-4729-907c-75d8f99a6c85 | publisher = | date = | accessdate = 4 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Beta blockers]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |